Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

ESMO 2025: VT3989 Continues to Show Promising Early Results in Patients with Advanced Mesothelioma

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

October 19, 2025


October 19 2025

October 18 2025

October 17 2025

October 16 2025

October 15 2025

October 14 2025

October 13 2025

October 12 2025

October 11 2025

October 10 2025

October 9 2025

October 8 2025

October 7 2025

October 6 2025

October 5 2025